LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

Search

TG Therapeutics Inc

Chiusa

SettoreSettore sanitario

31.93 4.89

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

30.25

Massimo

32.08

Metriche Chiave

By Trading Economics

Entrata

363M

391M

Vendite

21M

162M

P/E

Media del settore

11.079

106.172

Margine di Profitto

241.727

Dipendenti

374

EBITDA

-4.9M

33M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+47.78% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-473M

4.9B

Apertura precedente

27.04

Chiusura precedente

31.93

Notizie sul Sentiment di mercato

By Acuity

35%

65%

102 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

TG Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 nov 2025, 22:42 UTC

Discorsi di Mercato

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21 nov 2025, 21:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

21 nov 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

21 nov 2025, 21:47 UTC

Discorsi di Mercato

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21 nov 2025, 21:43 UTC

Discorsi di Mercato

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21 nov 2025, 20:18 UTC

Discorsi di Mercato

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21 nov 2025, 20:14 UTC

Discorsi di Mercato

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21 nov 2025, 19:48 UTC

Discorsi di Mercato

Precious Metals Fall for the Week -- Market Talk

21 nov 2025, 19:44 UTC

Utili

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21 nov 2025, 19:37 UTC

Discorsi di Mercato

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21 nov 2025, 19:27 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

21 nov 2025, 19:27 UTC

Discorsi di Mercato
Utili

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21 nov 2025, 19:20 UTC

Discorsi di Mercato

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21 nov 2025, 18:44 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21 nov 2025, 18:37 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21 nov 2025, 18:34 UTC

Discorsi di Mercato
Utili

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21 nov 2025, 18:28 UTC

Utili

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 nov 2025, 18:03 UTC

Discorsi di Mercato

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21 nov 2025, 17:24 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

21 nov 2025, 17:24 UTC

Discorsi di Mercato

Intuit Seen on Path to Increase Growth -- Market Talk

21 nov 2025, 17:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

21 nov 2025, 17:05 UTC

Discorsi di Mercato

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

21 nov 2025, 16:56 UTC

Discorsi di Mercato

Gold Recovers as Investors Boost Rate-Cut Bets -- Market Talk

21 nov 2025, 16:47 UTC

Discorsi di Mercato

European Gas-Price Forecast to Decline Further on Expanding LNG Supply -- Market Talk

21 nov 2025, 16:35 UTC

Acquisizioni, Fusioni, Takeovers

What Stocks Al Gore's Investment Firm Bought and Sold This Quarter -- Barrons.com

21 nov 2025, 16:09 UTC

Utili

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 nov 2025, 15:59 UTC

Discorsi di Mercato

Canadian Consumers Tapping the Brakes, Still See Resilient -- Market Talk

21 nov 2025, 15:59 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

21 nov 2025, 15:23 UTC

Discorsi di Mercato

Bank of Canada Not Expected to Be Swayed by Canadian Retail Trade Data -- Market Talk

21 nov 2025, 15:17 UTC

Discorsi di Mercato

Canadian Consumer Spending Softening, But Could Be Worse -- Market Talk

Confronto tra pari

Modifica del prezzo

TG Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

47.78% in crescita

Previsioni per 12 mesi

Media 45 USD  47.78%

Alto 60 USD

Basso 11 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per TG Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

4

Acquista

0

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

N/A / 34.86Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

102 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat